Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for G9TY5A101 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
AI Biotechnology LLC
13D/A
|
18.2% |
3/2/2026
Event 2/26/2026
|
||
| AI Biotechnology LLC | 18.2% | |||
| Access Industries Holdings LLC | 18.2% | |||
| Access Industries Management, LLC | 18.2% | |||
| Len Blavatnik | 18.2% | |||
|
Athanor Capital
13D
|
15.7% |
1/27/2026
Event 1/23/2026
|
||
| Athanor Capital | 15.7% | |||
| UGS Capital LLC | 15.7% | |||
|
Venrock Healthcare Capital Partners III, L.P.
13G/A
|
9.9% |
5/15/2026
Event 3/31/2026
|
||
| Venrock Healthcare Capital Partners III, L.P. | 9.9% | |||
| VHCP Co-Investment Holdings III, LLC | 9.9% | |||
| Venrock Healthcare Capital Partners EG, L.P. | 9.9% | |||
| VHCP Management III, LLC | 9.9% | |||
| VHCP Management EG, LLC | 9.9% | |||
| Nimish Shah | 9.9% | |||
| Bong Y. Koh | 9.9% | |||
|
Suvretta Capital Management, LLC
13G/A
|
9.9% |
5/12/2026
Event 3/31/2026
|
||
| Suvretta Capital Management, LLC | 9.9% | |||
| Averill Master Fund, Ltd. | 8.8% | |||
| Aaron Cowen | 9.9% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (6) | ||||
|
RA Capital Management, L.P.
13G/A
|
4.9% |
2/14/2025
Event 12/31/2024
|
||
| RA Capital Management, L.P. | 4.9% | |||
| Peter Kolchinsky | 4.9% | |||
| Rajeev Shah | 4.9% | |||
| RA Capital Healthcare Fund, L.P. | 4.9% | |||
| JPMorgan Chase & Co 13G/A | 4.7% |
5/6/2026
Event 4/30/2026
|
||
| Pfizer Inc 13G/A | 4.6% |
2/12/2025
Event 12/31/2024
|
||
|
Great Point Partners, LLC
13G/A
|
4.4% |
5/15/2026
Event 3/31/2026
|
||
| Great Point Partners, LLC | 4.4% | |||
| Dr. Jeffrey R. Jay, M.D. | 4.4% | |||
| Ms. Lillian Nordahl | 4.4% | |||
|
ADAR1 Capital Management, LLC
13G/A
|
3.2% |
2/14/2025
Event 12/31/2024
|
||
| ADAR1 Capital Management, LLC | 3.2% | |||
| ADAR1 Capital Management GP, LLC | 2.4% | |||
| Daniel Schneeberger | 3.2% | |||
|
Deep Track Capital, LP
13G/A
|
0.4% |
11/14/2025
Event 9/30/2025
|
||
| Deep Track Capital, LP | 0.4% | |||
| Deep Track Biotechnology Master Fund, Ltd. | 0.4% | |||
| David Kroin | 0.4% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 2 | 5.61 k | $23.3 k |
| 2026 Q2 | 99 | 72.9 M | $430 M |
| 2026 Q1 | 98 | 66.8 M | $396 M |
| 2025 Q4 | 81 | 44.9 M | $235 M |
| 2025 Q3 | 72 | 45.8 M | $198 M |
| 2025 Q2 | 66 | 35.3 M | $37.1 M |
| 2025 Q1 | 77 | 45.7 M | $59.0 M |
| 2024 Q4 | 94 | 42.9 M | $107 M |
| 2024 Q3 | 86 | 37.2 M | $151 M |
| 2024 Q2 | 60 | 33.0 M | $115 M |
| 2024 Q1 | 49 | 14.9 M | $37.7 M |
| 2023 Q4 | 49 | 15.3 M | $71.1 M |
| 2023 Q3 | 43 | 14.1 M | $93.3 M |
| 2023 Q2 | 40 | 12.8 M | $105 M |
| 2023 Q1 | 3 | 25.7 k | $24.7 k |